NEW YORK, NY--(Marketwired - Oct 1, 2014) - Pluristem Therapeutics Inc. (
Interested investors may get more information and a copy of the coverage report at http://acceleronequity.net/Acceleron_PSTIReport.pdf
- PSTI is currently pursuing the development of its PLX cells for 12 different indications that are in various stages of development, from preclinical to Phase II, throughout the world.
-
The company's proprietary 3-dimensional cell growth methods and manufacturing facility have an estimated $1 billion worth of production capacity per year, setting PSTI apart from the rest of the cell therapy market.
-
United Therapeutics has licensed the exclusive global rights to PLX cells for the treatment of pulmonary arterial hypertension (PAH) in a deal valued at over $55 million.
-
CHA Bio&Diostech has licensed the rights to PLX cells for the treatment of peripheral artery disease (PAD) in South Korea, with deal terms including a 50/50 joint venture, CHA covering all costs of clinical trials and subsequently sharing post-commercialization profits equally with PSTI.
-
The U.S. National Institutes of Health are working with PSTI on a development program for PLX cells in the treatment of acute radiation syndrome (ARS).
About Acceleron Equity Research
Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.